Project Grant R01CA296831
Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
- This federal Project Grant award, with a total funding amount of $572,254.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant was awarded on February 1, 2025 to Purdue University to conduct research aimed at identifying the first selective inhibitors of the phospholipase C gamma (PLCγ) family members, PLCγ1 and PLCγ2. The research project will utilize novel fluorescent substrates developed by the university's lab, including...
- The U.S. National Cancer Institute awarded a $429,123 Project Grant to Purdue University under the Cancer Treatment Research federal grant program (CFDA 93.395) to develop improved inhibitors that selectively target the CBX8 chromatin reader domain. This research aims to address the mis-regulation of chromatin, which drives cancer progression and chemotherapy resistance. The project will focus on developing CBX8-selective inhibitors using DNA-encoded libraries and validating the selective...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $457,503.00 in funding to Purdue University to conduct research on the "POSTTRANSLATIONAL REGULATION OF MACROPINOCYTOSIS IN PANCREATIC CANCER". The research aims to improve understanding of the signaling mechanisms that regulate macropinocytosis, a critical metabolic process that enables pancreatic cancer cells to survive under nutrient stress conditions. The findings...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $395,724 to PPI Pharmaceuticals LLC to investigate a series of compounds called "Abbapolins" that inhibit the Polo-like Kinase 1 (PLK1) protein, which is a key regulator of cell division and a validated anti-cancer drug target. The project aims to further optimize the Abbapolin leads and evaluate their activity against colorectal cancers, including testing them on a panel of...
- The National Cancer Institute (NCI) awarded a $1,396,152 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Chicago. The grant, with a project period from December 5, 2024 to November 30, 2029, aims to examine the role of the BNIP3 gene and mitophagy (the selective degradation of mitochondria) in muscle atrophy during cancer cachexia, which is prevalent in pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse...
- The National Cancer Institute, a component of the National Institutes of Health, awarded a $249,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Vanderbilt University. The grant, spanning January 1, 2025 to December 31, 2027, will fund research to understand the kinetics of receptor tyrosine kinase (RTK) signaling and biased agonism in cancer. Specifically, the project will employ advanced single-molecule fluorescence microscopy techniques in living cells to...
- The National Cancer Institute (NCI) awarded a $654,197 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The General Hospital Corporation (Massachusetts General Hospital) to develop and characterize patient-derived xenograft (PDX) tumor models that represent the major molecular subtypes of pancreatic ductal adenocarcinoma (PDAC). The grant aims to: 1) define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies, 2) elucidate the contribution of...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $338,828 to Bioplatinum Technologies LLC to study the effects of new platinum anticancer drugs in pancreatic cancer. The project aims to exploit the high levels of chondroitin-4-sulfate (C4S) glycosaminoglycans in pancreatic tumors to enhance the delivery and efficacy of the polynuclear platinum complex (PPC) drug triplatin. The research will evaluate triplatin as a potential...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
- This federal Project Grant award of $693,075.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support research at Yale University focused on "Targeting Pancreatic Endocrine-Exocrine Signaling in Cancer Development with Incretin Mimetics". The project aims to investigate how incretin mimetics, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), may impact the risk and development of pancreatic ductal...